Document:

EXHIBIT 10.1

                            Agreement with Management

                                       33
<PAGE>

                                    AGREEMENT

We, Sixth Business  Service Group,  Inc., a Florida  corporation,  do agree with
you, our president,  director and management,  Michael T. Williams, as of May 1,
1999, as follows.

o     We will not sell any securities prior to the location of an acquisition or
      merger candidate.

o     The  costs  of   identifying,   investigating,   and  analyzing   business
      combinations  not  obtained  from  the  merger  fee  paid  to  us  by  the
      acquisition  candidate  will be paid with funds  contributed  as a capital
      contribution by our president.  Management will fund our cash requirements
      until an acquisition is closed. Management has placed no cap on the amount
      of funds they will lend.

o     We may not borrow funds and use the loan  proceeds to make payments to any
      officer, director, promoter or affiliate or associate of us.

o     We will not enter into a business combination with any company which is in
      any way wholly or partially  beneficially owned by any officer,  director,
      promoter or affiliate or associate of us.

o     We will not pay a finder's fee to any member of management  for locating a
      merger or acquisition candidate.

o     No member  of  management  intends  to or may seek and  negotiate  for the
      payment of finder's fees.

o     Other  fees may be paid to our  management  if and only if it is agreed by
      the acquisition  candidate in the merger  agreement.  Any such fee will be
      funded  by a fee the  acquisition  candidate  agrees to pay as part of the
      merger agreement. There is no minimum or maximum amount of fee that can be
      paid. The amount will be determined in  arms'-length  negotiations  in the
      merger agreement.

o     The only other  pecuniary  benefit to be  received  by  management  is the
      retention of a to-be-agreed percent of stock after the acquisition closes.
      There is no minimum or maximum amount of stock which can be retained.  The
      amount  will be  determined  in  arms'-length  negotiations  in the merger
      agreement.

o     Except as  described  above,  we will not  utilize  any other  methods  of
      payments by which management or current shareholders receive funds, stock,
      other assets or anything of value whether tangible or intangible

Sixth Business Service Group, Inc.,
a Florida corporation

By: /s/ Michael T. Williams ______________________
Michael T. Williams; president, director and management

/s/ Michael T. Williams
Michael T. Williams<PAGE>

                                                                    EXHIBIT 10.2

<PAGE>

                                LICENSE AGREEMENT

                                     BETWEEN

                                YUNINETWORKS INC.

                                       AND

                   THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

                                       FOR

                              CASE NO. SD 2000-052
<PAGE>

                                TABLE OF CONTENTS

Article 1:        Definitions

Article 2:        Grant

Article 3:        Considerations

Article 4:        Reports, Records and Payments

Article 5:        Patent Matters

Article 6:        Governmental Matters

Article 7:        Termination of Agreement

Article 8:        Limited Warranty and Indemnification

Article 9:        Use of Names and Trademarks

Article 10:       Miscellaneous Provisions

<PAGE>

                                              **Confidential Treatment Requested
                                            Under 17 C.F.R. ss.ss. 200.80(b)(4),
                                                              200.83 and 230.406

                                LICENSE AGREEMENT

This agreement ("Agreement") is made by and between YuniNetworks Inc., a
California corporation having an address at 12780 High Bluff Drive, Suite 270,
San Diego, California 92130 ("LICENSEE") and The Regents Of The University Of
California, a California corporation having its statewide administrative offices
at 1111 Franklin Street, Oakland, California 94607-5200 ("UNIVERSITY"),
represented by its San Diego campus having an address at University of
California, San Diego, Technology Transfer & Intellectual Property Services,
Mail-code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 ("UCSD").

This Agreement is effective on March 14, 2000 ("Effective Date").

                                    RECITALS

WHEREAS, the technical information and inventions disclosed in UCSD Case Docket
No. SD2000-052 and titled "A Scalable Terabit Switch Design with 40Gbps Link
Rate and Mechanisms to Support Earliest-deadline-first Scheduling in the Said
Switch" (collectively, the "Invention Disclosure"), were made in the course of
research at UCSD by Dr. Kenneth Yun and associates (hereinafter and
collectively, the "Inventors") and are covered by Patent Rights as defined
below;

WHEREAS, the research was sponsored in part by the Government of the United
States of America and as a consequence this license is subject to overriding
obligations to the Federal Government under 35 U.S.C. (S)(S)200-212
and applicable regulations;

WHEREAS, the Inventors are employees of UCSD, and they are obligated to assign
all of their right, title and interest in the Invention to UNIVERSITY;

WHEREAS, LICENSEE entered into a Letter of Intent (UC Control No. 2000-30-0138)
with UNIVERSITY, effective 16 October 1999, ("Letter of Intent"), for the
purpose of negotiating this Agreement;

WHEREAS, UNIVERSITY is desirous that the Invention be developed and utilized to
the fullest possible extent so that its benefits can be enjoyed by the general
public;

WHEREAS, LICENSEE is desirous of obtaining certain rights from UNIVERSITY for
commercial development, use, and sale of the Invention, and the UNIVERSITY is
willing to grant such rights; and

WHEREAS, LICENSEE understands that UNIVERSITY may publish or otherwise
disseminate information concerning the Invention (as defined below) at any time
and that LICENSEE is paying consideration thereunder for its early access to the
Invention, not continued secrecy therein.

                                       1.
<PAGE>

WHEREAS, the Invention was developed without Government support.

NOW, THEREFORE, the parties agree:

                             ARTICLE 1. DEFINITIONS

The terms, as defined herein, shall have the same meanings in both their
singular and plural forms.

1.1  "Affiliate" means any corporation or other business entity in which
     LICENSEE owns or controls, directly or indirectly, at least twenty percent
     (20%) of the outstanding stock or other voting rights entitled to elect
     directors, or in which LICENSEE is owned or controlled directly or
     indirectly by at least twenty percent (20%) of the outstanding stock or
     other voting rights entitled to elect directors; but in any country where
     the local law does not permit foreign equity participation of at least
     twenty percent (20%), then an "Affiliate" includes any company in which
     LICENSEE owns or controls or is owned or controlled by, directly or
     indirectly, the maximum percentage of outstanding stock or voting rights
     permitted by local law.

1.2  "Sublicensee" means a third party to whom LICENSEE grants a sublicense of
     certain rights granted to LICENSEE under this Agreement.

1.3  "Field" means the field of packet-switched communications including,
     without limitation, high-speed networked communications.

1.4  "Territory" means the entire world.

1.5  "Term" means the period of time beginning on the Effective Date and ending
     on the the expiration date of the last-to-expire patent in the Patent
     Rights.

1.6  "Patent Rights" means any of the following: the U.S. provisional patent
     application, Serial Number yet to be assigned, entitled "AN
     EARLIEST-DEADLINE-FIRST QUEUING PACKET SWITCHING ARCHITECTURE AND METHOD",
     filed 07 October 1999 by Inventors and assigned to UNIVERSITY (and any
     other patent applications based upon the Invention) and all applications
     claiming the priority thereof (collectively, the "parent application"),
     including continuing applications of the parent application and including
     divisions, substitutions, and continuations-in-part (but only to extent the
     claims thereof are enabled by disclosure of the parent application) of the
     parent application; any patents issuing on any of the above applications
     including reissues, reexaminations and extensions; and any corresponding
     foreign applications or patents.

1.7  "Invention" means all technical information, inventions (whether or not
     patentable) and know-how described within the Invention Disclosure,
     provided however that the Invention does not include any technical
     information, inventions or know-how

                                       2.
<PAGE>

     developed or discovered by LICENSEE without involving a UNIVERSITY
     employee, using UNIVERSITY facilities, or using funding received from the
     UNIVERSITY.

1.8  "Sponsor Rights" means all the applicable provisions of any license to the
     United States Government executed by UNIVERSITY and the overriding
     obligations to the Federal Government under 35 U.S.C. (S)(S)200-212 and
     applicable governmental implementing regulations.

1.9  "Licensed Method" means: (i) any method that uses the Invention, or (ii)
     any method, the use of which would constitute, but for the license granted
     to LICENSEE under this Agreement, an infringement of any pending or issued
     and unexpired claim within Patent Rights.

1.10 "Licensed Product" means any services, composition or product that: (i)
     uses the Invention or is produced by the Licensed Method, (ii) is covered
     by the claims of Patent Rights, and (iii) upon manufacture, use, sale,
     offer for sale, or importation would constitute, but for the license
     granted to LICENSEE by UNIVERSITY herein, an infringement of any pending or
     issued, unexpired and valid claim within the Patent Rights in the
     applicable country.

1.11 "Net Sublicensee Revenues" means the total of the gross revenues actually
     received by a Sublicensee from the sale of Licensed Products by such
     Sublicensee, less the sum of the following actual and customary deductions
     where applicable and separately listed: cash, trade, or quantity discounts;
     sales, use, tariff, custom, import/export duties or other excise taxes
     imposed on particular sales (except for value-added and income taxes
     imposed on the sales of Licensed Products in foreign countries); costs of
     insurance, packing, and transportation charges; or credits to customers
     because of rejections or returns. For purposes of calculating Net
     Sublicensee Revenues, transfers to an affiliate of Sublicensee of Licensed
     Product under this Agreement for (i) end use (but not resale) by such
     affiliate shall be treated as sales by such Sublicensee at list price of
     such Sublicensee, or (ii) resale by such affiliate shall be treated as
     sales at the list price of such affiliate.

1.12 "Patent Costs" means all out-of-pocket expenses for the preparation,
     filing, prosecution, and maintenance of all United States and foreign
     patents included in Patent Rights. Patent Costs shall also include
     reasonable out-of-pocket expenses for patentability opinions, inventorship
     determination, preparation and prosecution of patent application,
     re-examination, re-issue, interference, and opposition activities related
     to patents or applications in Patent Rights.

1.13 "Combination Product" means any product which is a Licensed Product and
     contains one or more other products or product components that (i) do not
     use Invention or Patent Rights; (ii) the sale, use or import by themselves
     do not contribute to the

                                       3.
<PAGE>

     infringement of Patent Rights; (iii) and enhance the market price of the
     final product(s) sold, used or imported by LICENSEE, its Sublicensee, or an
     Affiliate.

1.14 "Sublicensing Revenues" means the gross revenues actually received by
     LICENSEE (whether in the form of upfront payments, license fees, license
     maintenance fees, milestone payments, royalties, minimum royalties or
     advance royalties) from its sublicensees of the Patent Rights under this
     Agreement and allocable to the sublicensing of such Patent Rights.
     Sublicensing Revenues excludes specifically any amounts received by
     LICENSEE from a sublicensee (to the extent such amounts are unrelated to
     any sublicense of the Patent Rights or Invention) (i) as research and
     development funding or support payments, (ii) for the purchase of an equity
     interest in LICENSEE, (iii) as a loan to LICENSEE, or (iv) any advanced
     royalty payments, options or other payments to LICENSEE that are refundable
     to such sublicensee (collectively, "Refundable Payments"), but only until
     such time as such Refundable Payments become non-refundable. For the
     avoidance of doubt, Sublicensing Revenues shall not be deemed to include
     any royalty or other amounts payable LICENSEE in connection with any
     sublicensee's manufacture of Licensed Products or Combination Products for
     LICENSEE.

                                ARTICLE 2. GRANTS

2.1  License. Subject to the limitations set forth in this Agreement, UNIVERSITY
hereby grants to LICENSEE, and LICENSEE hereby accepts, a license under
UNIVERSITY's intellectual property rights in the Invention, including, without
limitation, the Patent Rights, to make, have made, use, sell, offer for sale,
distribute and import Licensed Products and to practice Licensed Methods and to
use the Invention, in the Field within the Territory and during the Term. The
license granted herein is exclusive and UNIVERSITY shall not grant to third
parties a further license under Patent Rights or to use the Invention in the
Field, within the Territory and during the Term.

2.2  Sublicense.

(a)  The license granted in Paragraph 2.1 includes the right of LICENSEE to
     grant sublicense to third parties during the Term but only for as long the
     license is exclusive.

(b)  With respect to sublicense granted pursuant to Paragraph 2.2(a), LICENSEE
     shall:

     (1)  not receive, or agree to receive, anything of value in lieu of cash as
          considerations from a third party under a sublicense granted pursuant
          to Paragraph 2.2(a) without the express written consent of UNIVERSITY,
          which shall not be withheld provided that LICENSEE can reasonably
          demonstrate the equivalent cash value of such considerations.

                                       4.
<PAGE>

     (2)  to the extent applicable, include all of the rights of and obligations
          due to UNIVERSITY (and, if applicable, the Sponsor's Rights) and
          contained in this Agreement;

     (3)  promptly provide UNIVERSITY with a copy of a summary of the
          non-confidential material terms of each sublicense issued; and

     (4)  collect and forward payment of all payments due, directly or
          indirectly, to UNIVERSITY from Sublicensees and summarize and deliver
          all reports due, directly or indirectly, to UNIVERSITY from
          Sublicensees.

(c)  Upon termination of this Agreement for any reason, UNIVERSITY, at its sole
     discretion, shall determine whether LICENSEE shall cancel or assign to
     UNIVERSITY any and all Sublicenses. In the event UNIVERSITY elects to
     cancel the sublicense of any Sublicensee, such Sublicensee may make a
     written request to University to enter into negotiations for a license
     agreement with UNIVERSITY. UNIVERSITY agrees to negotiate in good faith a
     license agreement, with a grant of rights similar in scope to that granted
     by LICENSEE to such Sublicensee, with terms and conditions substantially
     equivalent to those in this Agreement.

2.3  Reservation of Rights. UNIVERSITY reserves the right to:

(a)  use the Invention and Patent Rights exclusively for educational and
     research purposes, but except as otherwise provided herein shall not in any
     way use, sublicense, or allow use of, the Invention and Patent Rights for
     any commercial purpose; and

(b)  publish or otherwise disseminate any information about the Invention at any
     time; provided however that UNIVERSITY shall provide Licensee thirty (30)
     days prior notice of any contemplated publication or dissemination of such
     information together with an advance copy thereof.

(c)  allow other nonprofit institutions to use Invention and Patent Rights for
     educational and non-commercial research purposes in their facilities.

2.4  Improvements. All improvements or developments to the Invention made solely
     by employees or agents of LICENSEE shall be the sole property of LICENSEE.

                            ARTICLE 3. CONSIDERATIONS

3.1  Fees and Royalties. The parties hereto understand that the fees and
     royalties payable by LICENSEE to UNIVERSITY under this Agreement are
     partial considerations for the license granted herein to LICENSEE under the
     Invention, and Patent Rights. LICENSEE shall pay UNIVERSITY, during the
     Term:

                                       5.
<PAGE>

     (a)  a license fee of [...***...] payable within [...***...] of the
          Effective Date;

     (b)  license user fees of [...***...] per year accruing during the
          [...***...] following the Effective Date and payable on [...***...] of
          the Effective Date; and annual technology usage fees of [...***...]
          accruing beginning as of the [...***...] of the Effective Date and
          payable on the [...***...] of the Effective Date and on [...***...] of
          the Effective Date thereafter during the Term; and

     (c)  [...***...] of [...***...] sublicense fees received by Licensee from
          its sublicensees that are not [...***...], and [...***...] sublicense
          royalty payment received by licensee from its sublicensees on
          [...***...] of [...***...], the [...***...] of the [...***...]; or
          [...***...] of the [...***...].

     All fees and royalty payments specified in Paragraphs 3.1(a) through 3.1(c)
     above shall be paid by LICENSEE pursuant to Paragraph 4.3 and shall be
     delivered by LICENSEE to UNIVERSITY as noted in Paragraph 10.1.

3.2  Patent costs. Licensee shall reimburse University [...***...] Patent Costs
[...***...] within thirty (30) days following receipt by LICENSEE of an itemized
invoice from UNIVERSITY.

3.3  Due Diligence.

     (a)  LICENSEE shall:

     (1)  use reasonable efforts to effect introduction of the Licensed Products
          into the commercial market as soon as practical consistent with sound
          and reasonable business practices and judgment;

     (2)  annually spend not less than [...***...] U.S. Dollars (US$[...***...])
          for the development of Licensed Products during the first [...***...]
          years of this Agreement. LICENSEE may, at its sole option, fund the
          research of any one of the Inventors and credit the amount of such
          funding actually paid to UCSD against its obligation under this
          paragraph;

     (3)  submit to UNIVERSITY a development, marketing, distribution, and
          sublicensing plan covering Licensed Products worldwide within
          [...***...] from the Effective Date of this Agreement;

                                       6.

* Confidential Treatment Requested

<PAGE>

     (4)  use reasonable commercial efforts to have the first sale and shipment
          of a Licensed Product in the United States occur within thirty-six
          months of the Effective Date of this Agreement;

     (5)  use reasonable commercial efforts to fill the market demand for
          Licensed Products following commencement of marketing at any time
          during the term of this Agreement; and

     (6)  use reasonable commercial efforts to obtain all necessary governmental
          approvals world-wide for the manufacture, use and sale of Licensed
          Products if and as required.

     (b) If LICENSEE fails to perform any of its obligations specified in
Paragraphs 3.3(a)(1)-(6), then UNIVERSITY shall so notify LICENSEE of failure to
perform. LICENSEE shall have the right and option to extend the target date of
any such diligent obligation for a period of [...***...] upon the payment of
$[...***...] within thirty (30) days of the extension date for each [...***...]
extension option exercised by LICENSEE. Should LICENSEE opt not to extend the
obligation or fail to meet it by the extended target date, then UNIVERSITY shall
have the right and option to either terminate this Agreement or change
LICENSEE'S exclusive license to a nonexclusive license. This right, if exercised
by UNIVERSITY, supersedes the rights granted in Article 2. The right to
terminate this Agreement or reduce LICENSEE's exclusive license granted
hereunder to a non-exclusive license shall be UNIVERSITY'S sole remedy for
breach of Paragraph 3.3. However, if LICENSEE is unable to perform any of the
due diligence obligations set forth in Paragraph 3.3 due to hardships beyond
LICENSEE's control while LICENSEE has demonstrated diligent commercial efforts
to perform these obligations, then UNIVERSITY may extend the dates as
appropriate (after conferring with LICENSEE in good faith and, in any event, as
appropriate and as needed) in writing to LICENSEE, and UNIVERSITY shall not
terminate this Agreement or reduce LICENSEE's exclusive license to a
non-exclusive license.

     (c) At the request of either party, any controversy or claim arising out of
or relating to the diligence provisions of Paragraph 3.3 shall be settled by
arbitration conducted in San Diego, CA in accordance with the then current
Licensing Agreement Arbitration Rules of the American Arbitration Association.
Judgment upon the award rendered by the arbitrator(s) shall be binding on the
parties and may be entered by either party in the court or forum, state or
federal, having jurisdiction. In determination of due diligence, the arbitrator
may determine solely the issues of fact or law with respect to termination of
LICENSEE's or UNIVERSITY's respective rights under this Agreement but shall not
have the authority to award monetary damages or grant equitable relief

     (d) To exercise either the right to terminate this Agreement or to reduce
the license to a non-exclusive license for lack of diligence required in
Paragraph 3.3, UNIVERSITY must give LICENSEE written notice of the deficiency.
The LICENSEE thereafter has sixty (60) days to cure the deficiency or to request
arbitration. If

                                       7.

* Confidential Treatment Requested
<PAGE>

UNIVERSITY has not received a written request for arbitration or satisfactory
tangible evidence that the deficiency has been cured by the end of the sixty
(60) day period, then UNIVERSITY may, at its option, either terminate the
Agreement or reduce LICENSEE's exclusive license to a non-exclusive license by
giving written notice to LICENSEE. These notices shall be subject to Paragraph
10.1 (Correspondence).

                    ARTICLE 4. REPORTS, RECORDS AND PAYMENTS

4.1  Reports.

(a)  Progress Reports.

     (1)  Beginning one (1) year after the Effective Date and ending on the date
          of first commercial sale of a Licensed Product in the United States,
          LICENSEE shall submit to UNIVERSITY semi-annual progress reports
          covering LICENSEE'S (and Affiliate's and Sublicensee's) activities to
          develop and test all Licensed Products and obtain any and all
          governmental approvals necessary for marketing the same. Such reports
          shall include a summary of work completed; summary of work in
          progress; current schedule of anticipated events or milestones; market
          plans for introduction of Licensed Products; and summary of resources
          (dollar value) spent in the reporting period.

     (2)  LICENSEE shall also report to UNIVERSITY, in its immediately
          subsequent progress report, the date of first commercial sale of a
          Licensed Product in each country.

(b)  Royalty Reports. After the first commercial sale of a Licensed Product
     anywhere in the world, LICENSEE shall submit to UNIVERSITY quarterly
     royalty reports on or before each February 28, May 31, August 31 and
     November 30 of each year. Each royalty report shall cover LICENSEE'S (and
     each Affiliate's and Sublicensee's) most recently completed calendar
     quarter and shall show:

     (1)  Sublicensing Revenues received during the most recently completed
          calendar quarter in US dollars, payable with respect thereto;

     (2)  the method used to calculate the royalties on such Sublicensing
          Revenues; and

     (3)  the exchange rates used.

                                       8.
<PAGE>

     If no Sublicensing Revenues have been received by LICENSEE during any
     reporting period, LICENSEE shall so report.

4.2  Records & Audits.

(a)  LICENSEE shall keep, and shall require its Affiliates and Sublicensees to
     keep, accurate and correct records of all Licensed Products manufactured,
     used, and sold, and sublicense fees received under this Agreement. Such
     records shall be retained by LICENSEE for at least five (5) years following
     a given reporting period.

(b)  All records shall be available during normal business hours for inspection
     at the expense of UNIVERSITY by a Certified Public Accountant selected by
     UNIVERSITY, and reasonably acceptable to LICENSEE, and in compliance with
     the other terms of this Agreement for the sole purpose of verifying reports
     and payments. Such inspector shall be bound to hold all information in
     confidence and shall not disclose to UNIVERSITY any information other than
     information relating to the accuracy of reports and payments made under
     this Agreement or other compliance issues. In the event that any such
     inspection shows an under reporting and underpayment in excess of five
     percent (5%) for any twelve (12) month period, then LICENSEE shall pay the
     cost of the audit as well as any additional sum that would have been
     payable to UNIVERSITY had the LICENSEE reported correctly, plus an interest
     charge at a rate of ten percent (10%) per year. Such interest shall be
     calculated from the date the correct payment was due to UNIVERSITY up to
     the date when such payment is actually made by LICENSEE. For underpayment
     not in excess of five percent (5%) for any twelve (12) month period,
     LICENSEE shall pay the difference within thirty (30) days without interest
     charge or inspection cost. In the event of any overpayment, UNIVERSITY
     shall credit, against future amounts payable by LICENSEE, any amounts paid
     by LICENSEE in excess of the amount of the correct payment due LICENSEE.

4.3  Payments.

(a)  All fees and royalties due UNIVERSITY shall be paid in United States
     dollars and all checks shall be made payable to "The Regents of the
     University of California", referencing UNIVERSITY'S taxpayer identification
     number, 95-6006144. When Licensed Products are sold in currencies other
     than United States dollars, LICENSEE shall first determine the earned
     royalty in the currency of the country in which Licensed Products were sold
     and then convert the amount into equivalent United States funds, using the
     exchange rate quoted in the Wall Street Journal on the last business day of
     the applicable reporting period.

(b)  Royalty Payments.

                                       9.
<PAGE>

     (1)  Royalties shall accrue when the Sublicensing Revenues upon which such
          royalties are based actually arise.

     (2)  LICENSEE shall pay earned royalties due to Sublicensing Revenues
          quarterly on or before February 28, May 31, August 31 and November 30
          of each calendar year. Each such payment shall be for such earned
          royalties accrued within LICENSEE'S most recently completed calendar
          quarter.

     (3)  Royalties earned on sales occurring or under sublicense granted
          pursuant to this Agreement in any country outside the United States
          shall not be reduced by LICENSEE for any taxes, fees, or other charges
          imposed by the government of such country on the payment of royalty
          income, except that all payments made by LICENSEE in fulfillment of
          UNIVERSITY'S tax liability in any particular country may be credited
          against earned royalties or fees due UNIVERSITY for that country.
          LICENSEE shall pay all bank charges resulting from the transfer of
          such royalty payments.

     (4)  If at any time legal restrictions prevent the prompt remittance of
          part or all royalties by LICENSEE with respect to any country where a
          Licensed Product is sold or a sublicense is granted pursuant to this
          Agreement, LICENSEE shall convert the amount owed to UNIVERSITY into
          US currency and shall pay UNIVERSITY fifty percent (50%) of such
          amount directly from its US sources of fund for as long as the legal
          restrictions apply, and the remainder of such amount within thirty
          (30) days of the removal of any such restrictions; provided however
          that LICENSEE shall be obligated to pay UNIVERSITY prior to the
          removal of such restrictions only to the extent the making of any such
          payment will not have a material adverse effect on LICENSEE's capacity
          to do business in the normal course.

     (5)  LICENSEE shall not collect royalties from, or cause to be paid on
          Licensed Products sold to the account of the US Government or any
          agency thereof as provided for in the license to the US Government.

     (6)  In the event that any patent or patent claim within Patent Rights is
          held invalid in a final decision by a patent office from which no
          appeal or additional patent prosecution has been or can be taken, or
          by a court of competent jurisdiction and last resort and from which no
          appeal has or can be taken, all obligation to pay royalties based
          solely on that patent or claim or any claim patentably indistinct
          therefrom shall cease as of the date of such final decision. LICENSEE
          shall not, however, be relieved from paying any royalties that accrued
          before the date of such final decision, that are based on another
          patent or claim not involved in such final

                                       10.
<PAGE>

          decision, or that are based solely on LICENSEE's internal use of the
          Invention.

(b)  Late Payments. In the event royalty, reimbursement and/or fee payments are
     not received by UNIVERSITY when due, LICENSEE shall pay to UNIVERSITY
     interest charges at a rate of one percent (1%) per month. Such interest
     shall be calculated from the date payment was due until actually received
     by UNIVERSITY. The payment of such interest shall not foreclose UNIVERSITY
     from exercising any other rights it may have as a consequence of the
     lateness of any payment. In no event shall this paragraph be construed as a
     grant of permission for any payment delays.

                            ARTICLE 5. PATENT MATTERS

5.1  Patent Prosecution and Maintenance.

(a)  Provided that LICENSEE has reimbursed UNIVERSITY for Patent Costs pursuant
     to Paragraph 3.2, UNIVERSITY shall diligently prosecute and maintain the
     United States and, if available, foreign patents, and applications in
     Patent Rights using counsel of its choice. UNIVERSITY shall provide
     LICENSEE with copies of all relevant documentation relating to such
     prosecution and LICENSEE shall keep this documentation confidential. The
     counsel shall take instructions only from UNIVERSITY, and all patents and
     patent applications in Patent Rights shall be assigned solely to
     UNIVERSITY.

(b)  Subsequent to the Initial Filing the UNIVERSITY shall provide LICENSEE with
     the opportunity to review any documentation pertinent to such prosecution
     prior to filing with the United States Patent and Trademark Office or
     applicable foreign governmental agency. UNIVERSITY shall reasonably
     consider amending any patent application in Patent Rights to include
     additional claims and technical description requested by LICENSEE to
     protect the products contemplated to be sold by LICENSEE under this
     Agreement; provided however that (i) UNIVERSITY shall not be obligated to
     make such amendment to the extent it can reasonably demonstrate to LICENSEE
     that such amendment would have a material adverse effect on the validity of
     any patent potentially issuing from such application, and (ii) any such
     additional claims need be enabled by the original or amended technical
     description in a patent application in Patent Rights.

(c)  LICENSEE may elect to terminate its reimbursement obligations with respect
     to any patent application or patent in Patent Rights upon three (3) months
     written notice to UNIVERSITY. UNIVERSITY shall use reasonable efforts to
     curtail further Patent Costs for such application or patent when such
     notice of termination is received from LICENSEE. UNIVERSITY, in its sole
     discretion

                                      11.
<PAGE>

     and at its sole expense, may continue prosecution and maintenance of said
     application or patent, and LICENSEE shall then have no further license with
     respect thereto. Non-payment of any portion of Patent Costs with respect to
     any application or patent may be deemed by UNIVERSITY as an election by
     LICENSEE to terminate its reimbursement obligations with respect to such
     application or patent; provided however that UNIVERSITY shall advise
     LICENSEE in writing of any such non-payment and shall provide LICENSEE a
     reasonable opportunity to make such payment prior to deeming such payment
     as such an election.

5.2  Patent Infringement.

(a)  If LICENSEE learns of any substantial infringement of Patent Rights,
     LICENSEE shall so inform UNIVERSITY and provide UNIVERSITY with reasonable
     evidence of the infringement. Neither party shall notify a third party of
     the infringement of Patent Rights without the consent of the other party.
     Both parties shall use reasonable efforts and cooperation to terminate
     infringement without litigation.

(b)  LICENSEE may request UNIVERSITY to take legal action against such third
     party for the infringement of Patent Rights. Such request shall be made in
     writing and shall include reasonable evidence of such infringement and
     damages to LICENSEE. If the infringing activity has not abated ninety (90)
     days following LICENSEE'S request, UNIVERSITY shall elect to or not to
     commence suit on its own account. UNIVERSITY shall give notice of its
     election in writing to LICENSEE by the end of the one-hundredth (100th) day
     after receiving notice of such request from LICENSEE, provided that
     LICENSEE may request UNIVERSITY to provide such notice prior to expiration
     of such 100 day period in consideration of LICENSEE's payment of a mutually
     agreed upon sum. LICENSEE may thereafter bring suit for patent infringement
     at its own expense, if and only if UNIVERSITY elects not to commence suit
     and the infringement occurred in a jurisdiction where LICENSEE has an
     exclusive license under this Agreement. If LICENSEE elects to bring suit,
     UNIVERSITY may join that suit at its own expense.

(c)  Recoveries from actions brought pursuant to Paragraph 5.2(b) shall belong
     to the party bringing suit. Legal actions brought jointly by UNIVERSITY and
     LICENSEE and fully participated in by both shall be at the joint expense of
     the parties and all recoveries shall be shared jointly by them in
     proportion to the share of expense paid by each party.

(d)  Each party shall cooperate with the other in litigation proceedings at the
     expense of the party bringing suit. Litigation shall be controlled by the
     party bringing the suit, except that UNIVERSITY may be represented by
     counsel of its choice, at its sole expense, in any suit brought by LICENSEE
     and LICENSEE may be

                                      12.
<PAGE>

     represented by counsel of its choice, at its sole expense, in any action
     brought by UNIVERSITY.

5.3  Patent Marking. LICENSEE shall mark all Licensed Products made, used or
sold under the terms of this Agreement, or their containers, in accordance with
the applicable patent marking laws.

                         ARTICLE 6. GOVERNMENTAL MATTERS

6.1  Governmental Approval or Registration. If this Agreement or any associated
transaction is required by the law of any nation to be either approved or
registered with any governmental agency, LICENSEE shall assume all legal
obligations to do so. LICENSEE shall notify UNIVERSITY if it becomes aware that
this Agreement is subject to a United States or foreign government reporting or
approval requirement. LICENSEE shall make all necessary filings and pay all
costs including fees, penalties, and all other out-of-pocket costs associated
with such reporting or approval process.

6.2  Export Control Laws. LICENSEE shall observe all applicable United States
and foreign laws with respect to the transfer of Licensed Products and related
technical data to foreign countries, including, without limitation, the
International Traffic in Arms Regulations and the Export Administration
Regulations.

6.3  Preference for United States Industry. If LICENSEE sells a Licensed Product
or Combination Product in the US, LICENSEE shall manufacture said product
substantially in the US.

                     ARTICLE 7. TERMINATION OF THE AGREEMENT

7.1  Termination by The Regents. If LICENSEE fails to perform or violates any
term of this Agreement, then except as is otherwise provided by Paragraph 3.3
UNIVERSITY may give written notice of default ("Notice of Default") to LICENSEE.
If LICENSEE fails to cure the default within sixty (60) days of the Notice of
Default, UNIVERSITY may terminate this Agreement and the license granted herein
by a second written notice ("Notice of Termination") to LICENSEE. If a Notice of
Termination is sent to LICENSEE, this Agreement shall automatically terminate on
the effective date of that notice. Termination shall not relieve LICENSEE of its
obligation to pay any fees or royalties owed at the time of termination and
shall not impair any accrued right of UNIVERSITY.

7.2  Termination by Licensee.

(a)  LICENSEE shall have the right at any time and for any reason to terminate
     this Agreement upon a ninety (90) day written notice to UNIVERSITY. Said
     notice shall state LICENSEE'S reason for terminating this Agreement.

                                      13.
<PAGE>

(b)  Any termination under Paragraph 7.2(a) shall not relieve LICENSEE of any
     obligation or liability accrued under this Agreement prior to termination
     or rescind any payment made to UNIVERSITY or action by LICENSEE prior to
     the time termination becomes effective. Termination shall not affect in any
     manner any rights of UNIVERSITY arising under this Agreement prior to
     termination.

7.3  Survival on Termination. The following Paragraphs and Articles shall
survive the termination of this Agreement:

(a)  Article 4 (REPORTS, RECORDS AND PAYMENTS);

(b)  Paragraph 7.4 (Disposition of Licensed Products on Hand);

(c)  Paragraph 8.2 (Indemnification);

(d)  Article 9 (USE OF NAMES AND TRADEMARKS);

(e)  Paragraph 10.2 (Secrecy);

(e)  Paragraph 10.5 (Failure to Perform); and

(f)  Paragraph 7.3 (Survival on Termination).

7.4  Disposition of Licensed Products on Hand. Upon termination of this
Agreement, LICENSEE may dispose of all previously made or partially made
Licensed Product within a period of one hundred and twenty (120) days of the
effective date of such termination provided that the sale of such Licensed
Product by LICENSEE, its Sublicensees, or Affiliates shall be subject to the
terms of this Agreement, including but not limited to the rendering of reports
and payment of royalties required under this Agreement.

                 ARTICLE 8. LIMITED WARRANTY AND INDEMNIFICATION

8.1  Limited Warranty.

(a)  UNIVERSITY warrants that it has the lawful right to grant this license, and
     that it has not granted, and will not grant, any licenses to any other
     entity that would restrict rights granted hereunder.

(b)  THE LICENSE GRANTED HEREIN AND THE INVENTION ARE PROVIDED "AS IS" AND
     WITHOUT WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR A PARTICULAR
     PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. UNIVERSITY MAKES NO
     REPRESENTATION OR WARRANTY THAT THE LICENSED PRODUCT, LICENSED METHOD OR
     THE USE OF PATENT RIGHTS WILL NOT

                                      14.
<PAGE>

     INFRINGE ANY OTHER PATENT OR OTHER PROPRIETARY RIGHTS; PROVIDED HOWEVER
     THAT UNIVERSITY IS NOT AWARE OF ANY SUCH INFRINGEMENT AS OF THE EFFECTIVE
     DATE.

(c)  IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY INCIDENTAL, SPECIAL OR
     CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS)
     RESULTING FROM PERFORMANCE OR FAILURE TO PERFORM UNDER THIS AGREEMENT,
     EXERCISE OF THE LICENSE GRANTED HEREIN OR THE USE OF THE INVENTION,
     LICENSED PRODUCT, OR LICENSED METHOD.

(d)  Nothing in this Agreement shall be construed as:

     (1)  a warranty or representation by UNIVERSITY as to the validity or scope
          of any Patent Rights;

     (2)  a warranty or representation that anything made, used, sold or
          otherwise disposed of under any license granted in this Agreement is
          or shall be free from infringement of patents of third parties;

     (3)  an obligation to bring or prosecute actions or suits against third
          parties for patent infringement except as provided in Paragraph 5.2
          hereof;

     (4)  conferring by implication, estoppel or otherwise any license or rights
          under any patents of UNIVERSITY other than Patent Rights as defined in
          this Agreement, regardless of whether those patents are dominant or
          subordinate to Patent Rights; provided however that should any such
          patent of UNIVERSITY cover a Licensed Product ("Relevant Patent"),
          then UNIVERSITY shall proceed as provided in subsection (e) below in
          connection with licensing of such Relevant Patent;

     (5)  an obligation to furnish any know-how not provided in Patent Rights
          and the Invention; or

     (6)  an obligation to update the Invention.

(e)  UNIVERSITY shall provide LICENSEE prior written notice of its intent to
     license rights to any Relevant Patent and the proposed terms of such
     license (the "Offer"); provided however that (i) UNIVERSITY shall otherwise
     not be obligated to inform LICENSEE of the existence of any such Relevant
     Patent, and (ii) UNIVERSITY shall only be obligated to make such Offer to
     LICENSEE to the extent UNIVERSITY has the right to license such Relevant
     Patent to LICENSEE. During the 30-day period following such notice from
     UNIVERSITY, LICENSEE may accept the Offer or negotiate with UNIVERSITY

                                      15.
<PAGE>

     mutually acceptable modifications to such Offer (the "Amended Offer"). If,
     during such 30-day period, LICENSEE accepts the Offer or LICENSEE and
     UNIVERSITY agree in writing to an Amended Offer, then the parties will
     enter into a license agreement on the terms set forth in such Offer or
     Amended Offer within 60 days thereafter. If LICENSEE does not accept the
     Offer or LICENSEE and UNIVERSITY do not agree in writing to an Amended
     Offer during such 30-day period, or if the parties fail to enter into a
     license agreement on the terms set forth in the Offer or Amended Offer
     within such 60-day period, then, for 180 days thereafter, UNIVERSITY shall
     be free to license rights to such Relevant Patent to a third party on terms
     no more favorable to the third party than those last offered by UNIVERSITY
     to LICENSEE.

8.2  Indemnification.

(a)  LICENSEE shall indemnify, hold harmless, and defend UNIVERSITY, its
     officers, employees, and agents; the sponsors of the research that led to
     the Invention; and the Inventors of the patents and patent applications in
     Patent Rights and their employers against any and all claims, suits,
     losses, damage, costs, fees, and expenses resulting from or arising out of
     exercise of this license or any sublicense. This indemnification shall
     include, but not be limited to, any product liability.

(b)  In the event of any infringement or likely infringement by the Invention of
     any third party's intellectual property (collectively, "Infringing
     Rights"), the UNIVERSITY and LICENSEE shall cooperate in good faith and on
     a mutual and reasonable basis, with each party responsible for its
     respective expenses:
     (1)  To negotiate and settle and dispute with any such third party
          concerning the Infringing Rights, and otherwise resolve any such
          infringement and secure Licensee's continued rights to the Infringing
          Rights; and

     (2)  To make reasonable and equitable adjustment, if any, to the royalties
          paid or otherwise due under this Agreement in respect of licenses or
          other rights obtained by LICENSEE from third parties under such
          Infringing Rights in order for LICENSEE to continue exercise rights
          granted under this Agreement.

(c)  LICENSEE, at its sole cost and expense, shall insure its activities in
     connection with the work under this Agreement and, prior to selling any
     Licensed Products, obtain, keep in force and maintain insurance or an
     equivalent program of self insurance as follows:

     (1)  comprehensive or commercial general liability insurance (contractual
          liability included) with limits of at least: (i) each occurrence,
          $1,000,000; (ii) products/completed operations aggregate, $5,000,000;
          (iii) personal

                                      16.
<PAGE>

          and advertising injury, $1,000,000; and (iv) general aggregate
          (commercial form only), $5,000,000; and

     (2)  the coverage and limits referred to above shall not in any way limit
          the liability of LICENSEE.

(d)  LICENSEE shall furnish UNIVERSITY with certificates of insurance showing
     compliance with all requirements prior to selling any Licensed Products.
     Such certificates shall: (i) provide for thirty (30) day advance written
     notice to UNIVERSITY of any modification; (ii) indicate that UNIVERSITY has
     been endorsed as an additional insured under the coverage referred to
     above; and (iii) include a provision that the coverage shall be primary and
     shall not participate with nor shall be excess over any valid and
     collectable insurance or program of self-insurance carried or maintained by
     UNIVERSITY.

(e)  UNIVERSITY shall notify LICENSEE in writing of any claim or suit brought
     against UNIVERSITY in respect of which UNIVERSITY intends to invoke the
     provisions of this Article. LICENSEE shall keep UNIVERSITY informed on a
     current basis of its defense of any claims under this Article.

                     ARTICLE 9. USE OF NAMES AND TRADEMARKS

9.1  Nothing contained in this Agreement confers any right to use in
advertising, publicity, or other promotional activities any name, trade name,
trademark, or other designation of either party hereto (including contraction,
abbreviation or simulation of any of the foregoing). Unless required by law, the
use by LICENSEE of the name, "The Regents Of The University Of California" or
"The University of California" or the name of any campus of the University Of
California is prohibited, without the express written consent of UNIVERSITY.
Notwithstanding the foregoing, LICENSEE may use the name "The Regents Of The
University Of California" or "The University of California", "The University of
California, San Diego" or "UCSD" to indicate, as a factual matter, that LICENSEE
is utilizing technology developed or owned by the UNIVERSITY.

9.2  UNIVERSITY may disclose to the Inventors the terms and conditions of this
Agreement upon their request. If such disclosure is made, UNIVERSITY shall
request the Inventors not disclose such terms and conditions to others.

9.3  UNIVERSITY may acknowledge the existence of this Agreement and the extent
of the grant in Article 2 to third parties, but UNIVERSITY shall not disclose
the financial terms of this Agreement to third parties, except where UNIVERSITY
is required by law to do so, such as under the California Public Records Act.

                     ARTICLE 10.  MISCELLANEOUS PROVISIONS

                                      17.
<PAGE>

10.1 Correspondence. Any notice or payment required to be given to either party
under this Agreement shall be deemed to have been properly given and effective:

     (a)  on the date of delivery if delivered in person, or
     (b)  five (5) days after mailing if mailed by first-class or certified
          mail, postage paid, to the respective addresses given below, or to
          such other address as is designated by written notice given to the
          other party.

                  If sent to LICENSEE:
                  -------------------
                  YuniNetworks Inc.
                  Attention:  President
                  12780 High Bluff Drive, Suite 270
                  San Diego, California 92130

                  If sent to UNIVERSITY:
                  ---------------------
                  Technology Transfer & Intellectual Property Services
                  Attention:  Director
                  University of California, San Diego
                  9500 Gilman Drive, Mail Code 0910
                  La Jolla, CA 92093-0910

                  Phone:   858.534.5815
                  Fax:     858.534.7345

10.2 Secrecy.

(a)  "Confidential Information" shall mean information, including know-how and
     technical information, relating to the Invention and disclosed by one party
     ("Disclosing Party") to the other party ("Receiving Party") during the term
     of this Agreement, which if disclosed in writing shall be marked
     "Confidential", or if first disclosed otherwise, shall within thirty (30)
     days of such disclosure be reduced to writing by the Disclosing Party and
     sent to the Receiving Party:

(b)  The Receiving Party shall:

     (1)  use the Confidential Information for the sole purpose of performing
          under the terms of this Agreement;

     (2)  safeguard Confidential Information against disclosure to others with
          the same degree of care as it exercises with its own data of a similar
          nature;

     (3)  not disclose Confidential Information to others (except to its
          employees, agents or consultants who are bound to the Receiving Party
          by a like obligation of confidentiality) without the express written
          permission of the

                                      18.
<PAGE>

          Disclosing Party, except that the Receiving Party shall not be
          prevented from using or disclosing any of the Confidential Information
          that:

          (i)   the Receiving Party can demonstrate by written records was
                previously known to it;

          (ii)  is now, or becomes in the future, public knowledge other than
                through acts or omissions of the Receiving Party; or

          (iii) is lawfully obtained by the Receiving Party from sources
                independent of the Disclosing Party.

(b)  The secrecy obligations of the Disclosing Party with respect to
     Confidential Information shall continue for a period ending five (5) years
     from the termination date of this Agreement.

10.3 Assignability. This Agreement may be assigned by UNIVERSITY, but is
personal to LICENSEE and assignable by LICENSEE only with the written consent of
UNIVERSITY, which shall not be unreasonably withheld; provided however that
LICENSEE may assign this Agreement (i) in connection with the sale of
substantially all of LICENSEE's business to which this Agreement pertains, or
(ii) incident to a merger, acquisition or other corporate reorganization
involving LICENSEE.

10.4 No Waiver. No waiver by either party of any breach or default of any
covenant or agreement set forth in this Agreement shall be deemed a waiver as to
any subsequent and/or similar breach or default.

10.5 Failure to Perform. In the event of a failure of performance due under this
Agreement and if it becomes necessary for either party to undertake legal action
against the other on account thereof, then the prevailing party shall be
entitled to reasonable attorney's fees in addition to costs and necessary
disbursements.

10.6 Governing Laws. THIS AGREEMENT SHALL BE INTERPRETED AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, but the scope and validity
of any patent or patent application shall be governed by the applicable laws of
the country of the patent or patent application.

10.7 Force Majeure. A party to this Agreement may be excused from any
performance required herein if such performance is rendered impossible or
unfeasible due to any catastrophe or other major event beyond its reasonable
control, including, without limitation, war, riot, and insurrection; laws,
proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other
serious labor disputes; and floods, fires, explosions, or other natural
disasters. When such events have abated, the non-performing party's obligations
herein shall resume.

                                      19.
<PAGE>

10.8  Headings. The headings of the several sections are inserted for
convenience of reference only and are not intended to be a part of or to affect
the meaning or interpretation of this Agreement.

10.9  Entire Agreement. This Agreement embodies the entire understanding of the
parties and supersedes all previous communications, representations or
understandings, either oral or written, between the parties relating to the
subject matter hereof. All terms and conditions of any documents, purchase
orders, etc., issued by Company to facilitate payment hereunder are null and
void, even though they may be issued after the signing of this agreement.

10.10 Amendments. No amendment, alteration, or modification of this Agreement
shall be valid or binding on the parties unless made in writing and signed on
behalf of each party.

10.11 Severability. In the event that any of the provisions contained in this
Agreement is held to be invalid, illegal, or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other provisions
of this Agreement, and this Agreement shall be construed as if the invalid,
illegal, or unenforceable provisions had never been contained in it.

IN WITNESS WHEREOF, both UNIVERSITY and LICENSEE have executed this Agreement,
in duplicate originals, by their respective and duly authorized officers on the
day and year written.

YUNINETWORKS:                           THE UNIVERSITY OF THE
                                        UNIVERSITY OF CALIFORNIA:

By: /s/ Kay H. Yun                      By: /s/ Alan S. Paau
    ---------------                         ----------------
    Kay H. Yun                              Alan S. Paau
    President & CEO                         Director, Technology Transfer &
                                            Intellectual Property Services

Date: 3/13/2000                         Date: 3/14/2000
      ---------                               ---------

                                      20.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}]]